Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-read epigenomic diagnosis and prognosis of Acute Myeloid Leukemia.
Lamba J, Marchi F, Landwehr M, Schade AK, Shastri V, Ghavami M, Sckaff F, Marrero R, Nguyen N, Mansinghka V, Cao X, Slayton W, Starostik P, Ribeiro R, Rubnitz J, Klco J, Gamis A, Triche T Jr, Ries R, Kolb EA, Aplenc R, Alonzo T, Pounds S, Meshinchi S, Cogle C, Elsayed A. Lamba J, et al. Among authors: aplenc r. Res Sq [Preprint]. 2024 Dec 12:rs.3.rs-5450972. doi: 10.21203/rs.3.rs-5450972/v1. Res Sq. 2024. PMID: 39711573 Free PMC article. Preprint.
Automated Electronic Health Record Data Extraction and Curation Using ExtractEHR.
Miller TP, Getz KD, Krause E, Jo YG, Charapala S, Gramatages MM, Rabin K, Scheurer ME, Wilkes JJ, Fisher BT, Aplenc R. Miller TP, et al. Among authors: aplenc r. JCO Clin Cancer Inform. 2024 Nov;8:e2400100. doi: 10.1200/CCI.24.00100. Epub 2024 Nov 25. JCO Clin Cancer Inform. 2024. PMID: 39586036 Free PMC article.
Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy.
Friedes BD, DiNofia AM, Iannone E, Li Y, Rheingold SR, Barz Leahy A, Wray L, Callahan C, Baniewicz D, Vernau L, Getz KD, Aplenc R, Maude SL, Grupp SA, Myers RM. Friedes BD, et al. Among authors: aplenc r. Blood Adv. 2024 Nov 20:bloodadvances.2024014518. doi: 10.1182/bloodadvances.2024014518. Online ahead of print. Blood Adv. 2024. PMID: 39565957 No abstract available.
Cytokine-mediated CAR T therapy resistance in AML.
Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, Loken MR, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, Gill SI. Bhagwat AS, et al. Among authors: aplenc r. Nat Med. 2024 Dec;30(12):3697-3708. doi: 10.1038/s41591-024-03271-5. Epub 2024 Sep 27. Nat Med. 2024. PMID: 39333315 Clinical Trial.
Impact of Genetic Ancestry on T-cell Acute Lymphoblastic Leukemia Outcomes.
Teachey D, Newman H, Lee S, Pölönen P, Shraim R, Li Y, Liu H, Aplenc R, Bandyopadhyay S, Chen C, Chen Z, Devidas M, Diorio C, Dunsmore K, Elghawy O, Elhachimi A, Fuller T, Gupta S, Hall J, Hughes A, Hunger S, Loh M, Martinez Z, McCoy M, Mullen C, Pounds S, Raetz E, Ryan T, Seffernick A, Shi G, Sussman J, Tan K, Uppuluri L, Vincent TL, Wang'ondu R, Winestone L, Winter S, Wood B, Wu G, Xu J, Yang W, Mullighan C, Yang J, Bona K. Teachey D, et al. Among authors: aplenc r. Res Sq [Preprint]. 2024 Aug 16:rs.3.rs-4858231. doi: 10.21203/rs.3.rs-4858231/v1. Res Sq. 2024. PMID: 39184069 Free PMC article. Preprint.
Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials.
H Elsayed A, Cao X, Marrero RJ, Nguyen NHK, Wu H, Ni Y, Ribeiro RC, Tobias H, Valk PJ, Béliveau F, Richard-Carpentier G, Hébert J, Zwaan CM, Gamis A, Kolb EA, Aplenc R, Alonzo TA, Meshinchi S, Rubnitz J, Pounds S, Lamba JK. H Elsayed A, et al. Among authors: aplenc r. NPJ Precis Oncol. 2024 Aug 1;8(1):168. doi: 10.1038/s41698-024-00643-5. NPJ Precis Oncol. 2024. PMID: 39090192 Free PMC article.
Healthcare utilization disparities among children with high-risk neuroblastoma treated on Children's Oncology Group clinical trials.
Shoag J, Li Y, Getz KD, Huang YS, Hall M, Naranjo A, Richardson T, Desai AV, Umaretiya PJ, Aziz-Bose R, Kelly CA, Zheng DJ, Newman H, Zahler S, Aplenc R, Bagatell R, Bona K. Shoag J, et al. Among authors: aplenc r. Pediatr Blood Cancer. 2024 Oct;71(10):e31192. doi: 10.1002/pbc.31192. Epub 2024 Jul 12. Pediatr Blood Cancer. 2024. PMID: 38997807
Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group report.
Leger KJ, Absalon MJ, Demissei BG, Smith AM, Gerbing RB, Alonzo TA, Narayan HK, Hirsch BA, Pollard JA, Razzouk BI, Getz KD, Aplenc R, Kolb EA, Ky B, Cooper TM. Leger KJ, et al. Among authors: aplenc r. Front Cardiovasc Med. 2024 Jun 14;11:1347547. doi: 10.3389/fcvm.2024.1347547. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38947228 Free PMC article.
Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial.
van Dijk AD, Hoff FW, Qiu Y, Hubner SE, Go RL, Ruvolo VR, Leonti AR, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Horton TM, Kornblau SM. van Dijk AD, et al. Among authors: aplenc r. Cancers (Basel). 2024 Apr 9;16(8):1448. doi: 10.3390/cancers16081448. Cancers (Basel). 2024. PMID: 38672531 Free PMC article.
284 results